Swatton JE, Sellers LA, Faull RL, Holland A, Iritani S, Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur J Neurosci. 2004 May;19(10):2711-9. PubMed Abstract, View on AlzSWAN
RELATED PAPERSA survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains.Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.